Streetbeat News

AMIX

Autonomix Medical Inc.

Industry

Surgical and Medical Instrument Manufacturing

Open

2.04

Mkt cap

4.6M

Volume

58K

High

2.04

P/E Ratio

-0.11

52-wk high

75.80

Low

1.85

Div yield

N/A

52-wk low

1.83

Autonomix Medical, Inc. has completed the integration of its Apex 6 RF Generator, marking a key milestone as it advances toward U.S. clinical trials in 2025 for transvascular ablation.

Portfolio Pulse from

March 14, 2025 | 12:45 pm

Autonomix Medical, Inc. has released its financial results for the third quarter of fiscal year 2025 and provided a corporate update. The company is conducting a proof-of-concept clinical trial for pain associated with pancreatic cancer, with topline data expected in the first half of 2025.

Portfolio Pulse from

February 13, 2025 | 1:15 pm

Autonomix Medical, Inc. (NASDAQ: AMIX) has released a new CEO Corner segment featuring insights from the 43rd Annual J.P. Morgan Healthcare Conference and recent industry news.

Portfolio Pulse from

January 24, 2025 | 2:00 pm

Autonomix Medical, Inc. has finalized the design of its ASIC microchip for a sensing technology catheter, marking a significant milestone towards a U.S. pivotal trial in 2025. The company is advancing towards submitting an IDE for FDA approval.

Portfolio Pulse from

January 17, 2025 | 1:15 pm

Autonomix Medical, Inc. (NASDAQ: AMIX) will participate in the Virtual Investor Closing Bell Series on January 22, 2025. CEO Brad Hauser will provide a corporate overview and business outlook during the webcast.

Portfolio Pulse from

January 15, 2025 | 1:45 pm

Autonomix Medical, Inc. has been granted a U.S. patent for its catheter-based technology aimed at treating cancerous tumors and related pain. This adds to their growing patent portfolio, which includes over 80 issued patents. A preclinical study showed significant reductions in metastases and tumor mass.

Portfolio Pulse from

December 30, 2024 | 1:45 pm

Autonomix Medical, Inc. (NASDAQ: AMIX) has released a new CEO Corner segment where CEO Brad Hauser discusses the company's progress and future plans. This update is available on the company's website.

Portfolio Pulse from

December 23, 2024 | 1:45 pm

Autonomix Medical, Inc. has successfully closed a $10 million underwritten public offering, including a partial exercise of the over-allotment option. This funding will support the company's focus on precision nerve-targeted treatments.

Portfolio Pulse from

November 25, 2024 | 9:15 pm

Autonomix Medical, Inc. has announced the pricing of a $9.0 million underwritten public offering, involving common stock units and pre-funded warrant units.

Portfolio Pulse from

November 22, 2024 | 2:30 pm

Autonomix Medical, Inc. reported its Q2 FY2025 financial results and provided a corporate update. The company is conducting a proof-of-concept clinical trial for pain associated with pancreatic cancer, showing promising preliminary results with 100% of the lead-in patient responder group ceasing opioid use 4-6 weeks post-procedure.

Portfolio Pulse from

November 11, 2024 | 1:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.